Regulatory sources checked November 7, 2026. General sponsor guidance, not legal advice or an approval guarantee.
MSPAS, through DRCPFA, authorizes human clinical trials under Ministerial Agreement 206-2021, including a Phase I drug path and a separate device-investigation dossier. An authorized ethics committee approves the study before DRCPFA sees the file. A published pathway is not a site-readiness finding or a startup promise. For sponsors who need a larger national population than Panama, El Salvador, or Costa Rica, Guatemala (about 18.7 million people, World Bank, 2025) sits alongside the Dominican Republic (about 11.5 million) as an option to assess.
Bring the product description, development stage, preclinical evidence, proposed population, procedures, and follow-up. A Guatemala commitment should wait on a documented regulatory and operational plan for that protocol. This page does not claim that a study is already running or that a site is ready.
Guatemala has a published national framework for clinical trials in humans. The competent authority is the Ministry of Public Health and Social Assistance (MSPAS), through its Departamento de Regulación y Control de Productos Farmacéuticos y Afines (DRCPFA), under Ministerial Agreement 206-2021, published by MSPAS on 2 November 2021. The agreement includes Phase I drug requirements and a separate dossier for medical-device investigations.
Population is the reason sponsors look at Guatemala next to the Dominican Republic. The World Bank estimates about 18.7 million people in Guatemala in 2025, against about 11.5 million in the Dominican Republic and about 4.6 to 6.4 million in Panama, Costa Rica, and El Salvador (World Bank, World Development Indicators, SP.POP.TOTL, 2025). Guatemala’s national statistics office, INE, projects a lower figure of about 18.1 million for mid-2025, and the Dominican Republic’s 2022 census, run by ONE, counted about 10.8 million. A larger national population is not an enrollment forecast. Recruitment depends on the indication, protocol, investigator, and site.
For first-in-human sponsors who need a larger population base than Panama, El Salvador, or Costa Rica, bioaccess® positions Guatemala alongside the Dominican Republic as a country to assess for the protocol. That is a capability and approach statement, not a record of completed work: this page cites no completed Guatemala trials, sites, investigators, or patient numbers.
A protocol-specific feasibility assessment should establish whether the product, proposed population, investigator, site, and supporting evidence meet the current requirements. A published framework is not proof of a particular site’s readiness and not proof of a CRO’s local operating capacity. This page does not claim that bioaccess® is currently running a named Guatemala study.
Foreign data can be eligible for FDA submission and review under 21 CFR 812.28 only when that rule’s conditions are met, including ethics-committee oversight and informed consent. Eligibility is not clearance or approval. Guatemala observes UTC−6 year-round, with no daylight saving, so it matches U.S. Central time only while the United States is on standard time.
World Bank estimates for 2025 are 18,687,881 for Guatemala, 11,520,487 for the Dominican Republic, 6,365,503 for El Salvador, 5,152,950 for Costa Rica, and 4,571,189 for Panama (World Bank, World Development Indicators, SP.POP.TOTL, version of 11 November 2026). Guatemala is about 1.6 times the Dominican Republic by our calculation. INE Guatemala’s own projection for mid-2025 is lower, 18,079,810, and the Dominican Republic’s 2022 census (ONE) counted 10,773,983. Population is not an enrollment forecast.
MSPAS, through DRCPFA, under Ministerial Agreement 206-2021. An authorized ethics committee approves the study first (sections 37.8 and 42). Section 47 allows DRCPFA up to 30 business days after it receives complete documentation, with 15 business days for the applicant to answer a query. That statutory period is not an ethics-committee clock or a startup promise.
Start with Agreement 206-2021 and the current MSPAS forms. For a drug Phase I study, section 45.1 addresses the ethics opinion, consent and assent where applicable, a detailed protocol, a prior animal toxicity study that includes carcinogenicity and teratogenicity (section 45.1.5), the investigator brochure, and a facility and staff suitable for Phase I. Section 41.1 describes Phase I as conducted primarily in healthy individuals and, only by exception, in severely ill patients when no effective treatment is known. Each candidate needs its own assessment. This is not a statement that every drug or indication is eligible. Section 101 lists alternative conditions for an investigational product, including preclinical research aligned with MSPAS research policies and priorities. Do not paraphrase that list as a blanket requirement for prior foreign approval. For an investigational device, section 43 specifies device information, manufacturer and performance or safety documentation, a copy of the manufacturing-quality (Good Manufacturing Practice, GMP) certificate issued in the country of origin (section 43.3), relevant in-vitro and in-vivo evidence, investigator information, and the trial insurance policy. ISO 14155 can inform device good-clinical-practice planning. This page does not claim that Agreement 206-2021 expressly adopts it. Commercial device registration does not authorize research.
Guatemala commercial registration
Sections 37.8 and 42 require prior ethics approval before the application is presented to DRCPFA. Check the committee’s current authorization, relevant expertise, submission requirements, and meeting calendar. The official portal lists multiple ethics committees. Do not plan around a single national committee or one calendar for every committee. Section 38.7 requires each committee to set its own operating procedures, meeting frequency, and maximum response time, and to make those procedures available on request. The portal’s January 2026 roster is a snapshot. It is not proof that every listed committee remains authorized. Primary list: https://medicamentos.mspas.gob.gt/index.php/consultas/comites-de-etica-en-investigacion
Use the current F-EC-a-01 authorization form and the applicable registration forms for the sponsor, CRO or SMO, investigator, monitor, and site. The MSPAS forms portal has listed version 04-2025 of F-EC-a-01, effective 3 November 2025. Confirm the version when you file: https://medicamentos.mspas.gob.gt/index.php/formularios/formensayos. Section 42 includes ethics approval, site and investigator documentation, site contracts and permissions, the protocol, consent, investigator information, and insurance. The protocol must be in Spanish (section 42.11). The investigator brochure may be in its original language with a Spanish summary (section 42.12). Safety-report language has its own rule in section 118.7. Confirm translation and legalization for the actual dossier instead of assuming that every document needs both English and Spanish. A Spanish consent form makes understanding possible. Translation alone does not prove that a participant understood the study.
Section 47 states a regulatory authorization period of up to 30 business days after complete documentation is received. If additional information is requested, the applicant has 15 business days to respond, subject to the provision for explaining a delay in writing. The text then states a 15-business-day final-decision period after the required information is received. These provisions are not an ethics-review clock, a measured average, a promise of approval, or a total protocol-to-first-patient timeline. Ethics review, dossier preparation, queries, contracts, import, and activation are scheduled separately. The norm text: https://medicamentos.mspas.gob.gt/index.php/legislacion-vigente/acuerdos?download=336%3Aacuerdo-ministerial-206-2021
Before supply, confirm the ethics and DRCPFA documentation section 103.1 requires, the investigational-product import permissions and authorized import arrangements in the regulation, and protocol-specific storage and accountability. Complete contracts, training, safety oversight, insurance, and site-readiness checks before activation. Clinical-trial insurance must be in place before the study begins (section 11). Device applications include a policy copy (section 43.8). Approval, commercial registration, and shipment clearance are distinct. Section 48 provides a one-year authorization and a renewal requirement where it applies. Early-phase research evaluates safety questions. It is not a promise of efficacy or of direct benefit to the participant, and preclinical results do not prove human efficacy.
A clinical-trial authorization and a commercial MSPAS device registration are different files. The commercial framework sponsors use is Acuerdo Gubernativo 712-99, the Reglamento para el Control Sanitario de los Medicamentos y Productos Afines, as amended, together with Norma Técnica 37, version 5-2016, on the sanitary registration of medical devices (MSPAS Sources below). It is not a study permit. bioaccess® can process a manufacturer-funded registration as a scoped engagement. The legal holder, importer, and any transfer follow current MSPAS rules and local counsel. A distribution agreement does not override the regulator and does not guarantee a transfer. That commercial file does not replace DRCPFA study authorization or ethics review.
Commercial device registration
| Topic | Guatemala | United States | EU |
|---|---|---|---|
| Clinical-trial framework | Ministerial Agreement 206-2021 | 21 CFR 812 and IRB review | EU CTR or MDR, plus national ethics |
| Ethics timing | The committee’s own calendar | IRB-specific | Committee-specific |
| Authority clock | 30 business days from a complete file, plus query time | FDA’s own clocks | National competent-authority clocks |
| Regulator | MSPAS / DRCPFA | FDA | EMA and national authorities |
| FDA use of the data | Conditional under 21 CFR 812.28 | Domestic file | Conditional, with justification |
| Cost versus a U.S. program | Scoped to the protocol | Baseline | Scoped to the protocol |
| Clock versus the U.S. East Coast | UTC−6 all year | U.S. time zones | Typically 5 to 9 hours ahead |
Regulatory details reflect Agreement 206-2021 as checked on 7 November 2026. The 30-business-day period is not an ethics clock or a startup promise. Eligibility under 21 CFR 812.28 is not FDA clearance or approval. This page does not claim that the agreement expressly adopts ISO 14155. Commercial registration is quoted separately.
Use this page to see the published MSPAS sequence: product and site eligibility, ethics approval, the DRCPFA dossier, the complete-file clock, and import, insurance, and activation. Then ask for a feasibility assessment of the protocol in front of you.
Guatemala and the Dominican Republic are separate files with separate authorities. The Dominican Republic page sets out the DIGEMAPS and CONABIOS path; this page sets out the MSPAS and DRCPFA path. A sponsor weighing both is comparing population scale and pathway fit, not a promise about speed or cost.
Colombia, Brazil, and Venezuela have their own pages and their own authorities. A Guatemala plan does not relabel those files.
See the first-in-human CRO overview.
Next to Guatemala: clinical trials in the Dominican Republic.
Destination comparison: bioaccess® and Guatemala as a first-in-human destination.
Diligence questions: CRO in Guatemala.
Phase I drug file: first-in-human biopharma trials in Guatemala.
Device planning: orthopedic studies in Guatemala.
Commercial file: MSPAS device registration.
Population scale is the main reason. The World Bank estimates about 18.7 million people in Guatemala and about 11.5 million in the Dominican Republic for 2025, about 1.6 times as many (our calculation from the two figures). A larger national population is not an enrollment forecast, and this page claims no completed Guatemala studies, sites, investigators, or patient numbers. Ask for a protocol-specific feasibility assessment.
MSPAS, through DRCPFA, under Ministerial Agreement 206-2021. Ethics approval from an authorized committee comes before the Department reviews the application.
No. The official portal lists multiple ethics committees. Section 38.7 requires each committee to set its own procedures, meeting frequency, and maximum response time. A published roster is not proof that every committee is still authorized.
No. The protocol must be in Spanish. The investigator brochure may be in its original language with a Spanish summary. Confirm the language rule for the rest of the dossier, including safety reports, instead of assuming a bilingual set.
This page does not claim that. The agreement text checked on 7 November 2026 does not name ISO 14155. The standard can still inform device good-clinical-practice planning. Helsinki and good-clinical-practice duties are part of the national framework.
Section 45.1 sets Phase I drug requirements, including a prior animal toxicity study that covers carcinogenicity and teratogenicity (section 45.1.5), the investigator brochure, and a suitable Phase I facility. Section 41.1 says Phase I is conducted primarily in healthy individuals and only by exception in severely ill patients when no effective treatment is known. Section 43 sets the device-investigation dossier, including performance and safety documentation, a manufacturing-quality (GMP) certificate issued in the country of origin (section 43.3), and a copy of the trial policy. Commercial registration is neither of those files.
Section 47 allows up to 30 business days after a complete file is received. A query gives the applicant 15 business days to respond, and the text then allows 15 business days for a final decision after that information arrives. That is not an ethics clock and not a startup promise.
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when that rule’s conditions are met. Eligibility is not clearance or approval. Study design still has to satisfy the Guatemala ethics and MSPAS requirements.
No. Cost follows device or drug complexity, sites, participants, follow-up, imaging, import, and insurance. No savings percentage or faster-than-U.S. figure is stated here.
Commercial registration can be scoped as manufacturer-funded processing. It is a second file. The legal holder, importer, and any transfer follow current MSPAS rules and local counsel. A contract does not override the regulator, and a registration does not replace study authorization.
This page does not say that. Request a feasibility assessment for the protocol you actually have, and confirm a documented plan before you commit the country.
Last reviewed: November 2026
All countries we serve · Contact bioaccess® · First-in-Human CRO